产品
编 号：F251657
分子式：C8H13NO2
分子量：155.19
分子式：C8H13NO2
分子量：155.19
产品类型
规格
价格
是否有货
50mg
480
In-stock
100mg
800
In-stock
结构图
CAS No: 20448-79-7
产品详情
生物活性：
BCH (2-Amino-2-norbornanecarboxylic acid) is a selective and competitive inhibitor of large neutral amino acid transporter 1 (LAT1) significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis.
体内研究：
BCH (200 mg/kg; intravenous injection; daily; for 14 days; male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo.Animal Model:Male BALB/c nude mice (5-week-old) with KYSE150 cells
Dosage:200 mg/kg
Administration:Intravenous injection; daily; for 14 days
Result:Significantly delayed tumor growth and decreased glucose metabolism.
体外研究：
BCH (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner.BCH (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that BCH induces cell cycle arrest at G1 phase. BCH (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased.
BCH (2-Amino-2-norbornanecarboxylic acid) is a selective and competitive inhibitor of large neutral amino acid transporter 1 (LAT1) significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis.
体内研究：
BCH (200 mg/kg; intravenous injection; daily; for 14 days; male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo.Animal Model:Male BALB/c nude mice (5-week-old) with KYSE150 cells
Dosage:200 mg/kg
Administration:Intravenous injection; daily; for 14 days
Result:Significantly delayed tumor growth and decreased glucose metabolism.
体外研究：
BCH (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner.BCH (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that BCH induces cell cycle arrest at G1 phase. BCH (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备